AVANIR Pharmaceuticals, Inc.

ALISO VIEJO, Calif., Feb. 8, 2012 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) announced today that the results of the study entitled "Efficacy and Safety of Dextromethorphan/Quinidine (AVP-923) at Two Dosage Levels for Diabetic Neuropathic Pain: A Double-Blind, Placebo-Controlled, Multicenter Study" have been published in the February ... read more

ALISO VIEJO, Calif., Feb. 7, 2012 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three months ended December 31, 2011. Quarterly Financial Highlights -- Gross revenue for NUEDEXTA® of $6.3 million -- Total net revenues of $7.2 million ... read more

ALISO VIEJO, Calif., Jan. 30, 2012 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) will report financial results for the quarter ended December 31, 2011 after market close on Tuesday February 7, 2012. The company will conduct a conference call and an audio webcast at 1:30 pm Pacific ... read more

ALISO VIEJO, Calif., Dec. 12, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three and twelve months ended September 30, 2011. Quarterly Financial Highlights -- Cash, cash equivalents, and restricted investments of $81.8 million as ... read more

ALISO VIEJO, Calif., Dec. 6, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) will report financial results for the quarter and year ended September 30, 2011 after market close on Monday, December 12, 2011. The company will conduct a conference call and an audio webcast at 1:30 ... read more

ALISO VIEJO, Calif., Nov. 22, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that company management will participate in the Piper Jaffray 23rd Annual Health Care Conference. -- Piper Jaffray Health Care Conference -- Palace Hotel, New York, NY ... read more

ALISO VIEJO, Calif., Nov. 17, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) announced today that the European Medicines Agency (EMA) has accepted the filing of the Marketing Authorization Application (MAA) for NUEDEXTA® (dextromethorphan HBr and quinidine sulfate) for the treatment of pseudobulbar affect (PBA). Acceptance of the MAA confirms ... read more

ALISO VIEJO, Calif., Nov. 3, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the enrollment of the first patient in the PRIME study. The PRIME study is a Phase II clinical trial investigating the use of AVP-923 for the treatment of central neuropathic pain in patients with multiple ... read more

ALISO VIEJO, Calif., Oct. 31, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) announced today that it has submitted an application to the European Medicines Agency (EMA) seeking marketing authorization for NUEDEXTA® (dextromethorphan HBr and quinidine sulfate) for the treatment of pseudobulbar affect (PBA). NUEDEXTA was approved by the U.S. ... read more

ALISO VIEJO, Calif., Oct. 18, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data from clinical research activities will be highlighted at the 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Amsterdam, the Netherlands. ECTRIMS is ... read more

ALISO VIEJO, Calif., Oct. 12, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that pseudobulbar affect (PBA) prevalence data from stroke survivors will be highlighted at the 88th Annual Meeting of the American Congress of Rehabilitation Medicine/American Society for Neurorehabilitation Medicine in Atlanta, GA. Following are details about ... read more

ALISO VIEJO, Calif., Sept. 15, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that company management will participate in two upcoming investment conferences. The conference schedule is as follows: -- UBS Global Life Sciences Conference -- Grand ... read more

ALISO VIEJO, Calif., Aug. 31, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that company management will present an overview of the company at the Stifel Nicolaus Healthcare Conference in Boston, MA. -- Location: Four Seasons Hotel, Boston, MA -- ... read more